Active, not recruitingPhase 2NCT03503864
Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma
Studying Peripheral primitive neuroectodermal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Yang Li
- Principal Investigator
- Yang Li, ProfessorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Intervention
- Arsenic Trioxide(drug)
- Enrollment
- 80 target
- Eligibility
- 14 years · All sexes
- Timeline
- 2017 – 2028
Study locations (1)
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03503864 on ClinicalTrials.govOther trials for Peripheral primitive neuroectodermal tumor
Additional recruiting or active studies for the same condition.
See all trials for Peripheral primitive neuroectodermal tumor →